Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China
· Delayed Price · Currency is CNY 63.76
-0.27 (-0.42%)
Apr 29, 2026, 3:00 PM CST
SHA:688513 Revenue
Chengdu Easton Biopharmaceuticals had revenue of 326.26M CNY in the quarter ending March 31, 2026, with 6.75% growth. This brings the company's revenue in the last twelve months to 1.35B, up 0.87% year-over-year. In the year 2025, Chengdu Easton Biopharmaceuticals had annual revenue of 1.33B, down -1.36%.
Revenue (ttm)
1.35B
Revenue Growth
+0.87%
P/S Ratio
8.26
Revenue / Employee
888.31K
Employees
1,522
Market Cap
11.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.33B | -18.37M | -1.36% |
| Dec 31, 2024 | 1.35B | 232.63M | 20.82% |
| Dec 31, 2023 | 1.12B | -53.39M | -4.56% |
| Dec 31, 2022 | 1.17B | 147.58M | 14.43% |
| Dec 31, 2021 | 1.02B | 101.02M | 10.96% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hualan Biological Vaccine | 1.20B |
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.90B |
| Chongqing Genrix Biopharmaceutical | 230.72M |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |
| HitGen | 525.57M |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Jiangxi Fushine Pharmaceutical | 1.18B |